Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-06-01 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于召开2022年第三次临时股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2022 third extraordinary general meeting of shareholders for Tian Kang Biological Co., Ltd. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not on presenting financial results or management analysis. It is not a report itself but a formal announcement of a shareholder meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is 4275 characters, which is consistent with a detailed meeting notice rather than a full report or transcript.
2022-06-01 Chinese
关于新疆生产建设兵团国有资产经营有限责任公司向公司全资子公司天康制药（苏州）有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a non-public capital increase (增资) by a state-owned asset management company into a wholly-owned subsidiary of the company, Tian Kang Pharmaceutical (Suzhou) Co., Ltd. It discusses the related party transaction, board and supervisory approvals, independent directors' opinions, and the impact on shareholding structure. The document includes financial data, transaction purpose, and regulatory compliance statements. It is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a capital/financing update about a capital increase and related party transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7104 characters) and content support this classification with high confidence.
2022-06-01 Chinese
关于天康制药（苏州）有限公司混合所有制及员工持股改革实施方案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tian Kang Bio Co., Ltd. regarding the implementation plan for mixed ownership and employee stock ownership reform of its wholly-owned subsidiary Tian Kang Pharmaceutical (Suzhou) Co., Ltd. It details the restructuring plan, shareholder changes, capital increase, and governance adjustments. The document includes financial data of the subsidiary, the reform plan, and the impact on the listed company. It is a formal announcement of a corporate restructuring and capital change involving employee stock ownership and strategic investors, but it does not contain full financial statements or comprehensive financial performance data. It is not an annual or interim report, nor an earnings release or audit report. It is a capital/financing update related to equity restructuring and shareholding changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is about 4891 characters, sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2022-06-01 Chinese
独立董事事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a related-party transaction involving capital increase by a controlling shareholder to a subsidiary. It references compliance with listing rules and governance standards, and it is a pre-approval opinion submitted before a board meeting. The document is short (704 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or certification letter but a governance-related document concerning board procedures and approvals. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board-related decisions and management information.
2022-06-01 Chinese
天康制药（苏州）有限公司拟以增资扩股形式实施混合所有制及员工持股改革涉及的天康制药（苏州）有限公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is an asset valuation report for Tiankang Pharmaceutical (Suzhou) Co., Ltd., prepared by an asset appraisal company. It details the purpose, scope, valuation methods, and conclusions of the asset evaluation related to a capital increase and employee stock ownership reform. The report includes audited financial data, asset and liability details, and valuation results as of December 31, 2021. This is a specialized asset appraisal report, not a general financial report, earnings release, or regulatory announcement. It is a standalone audit/valuation report related to asset value assessment for a specific corporate action. Therefore, it fits best under the category of Audit Report / Information (AR). The document length and content confirm it is the full report, not just an announcement or certification. FY 2021
2022-06-01 Chinese
第七届董事会第二十八次(临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 28th (extraordinary) meeting of the 7th Board of Directors of Tian Kang Biological Co., Ltd. It includes details about the meeting date, attendance, agenda items, voting results, and references to related announcements and documents. The content focuses on board decisions and approvals, such as employee stock reform plans, capital increase proposals, and the calling of a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is not a full report but a board meeting resolution announcement. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (1478 characters), and it is not a report publication announcement or regulatory filing. Confidence is high due to clear identification of board meeting resolutions and voting results related to board matters.
2022-06-01 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.